(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) unveiled a new campaign commending the Biden Administration for delaying the Medicare prescription drug rebate rule, while calling for a complete Congressional repeal. “We applaud the Biden Administration for delaying the
The average dispensing fee in the commercial market is currently less than $2, while in comparison, $10.50 is a common dispensing fee in many states’ fee-for-service (FFS) Medicaid programs. If all states adopted a $10.50 dispensing fee on every commercial
PCMA Launches New Campaign Aimed at Repealing the Medicare Prescription Drug Rebate Rule March 1, 2021 ARTICLE (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) unveiled a new campaign commending the Biden Administration for delaying the Medicare prescription drug
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on today’s hearing in the Massachusetts House Committee on Post Audit and Oversight: “We applaud Massachusetts legislators for examining prescription drug pricing and share the objective of
Physician-administered drugs are those administered by a health care provider to a patient through injection or infusion, typically in a hospital outpatient setting or a provider’s office. Often high priced, these physician administered drugs represent a growing share of all
Pharmacy Benefit Managers reduce prescription drug costs for patients and use innovative technology to help patients get their prescriptions and lead healthier lives.
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called “delinking” proposals would be catastrophic for patients and families’ pocketbooks in a new op-ed in
Health Equity Working together for a more equitable health care system. Pharmacy benefit companies, in collaboration with plan sponsors, clinicians, and government programs, have a long history of working to advance health equity; however, the severity of the health disparities
This paper provides a quantitative model consistent with the theory and evidence in which pharmacy benefit management on behalf of insurance plans serves these and other purposes in both monopoly and oligopoly provider settings. Calibrating the model to the U.S.
©2024 PCMA. All Rights Reserved.
